Breath Test for Early Detection of Lung Cancer

Brief Summary

Official Title: “Breath Test Assay for the Adjunctive Detection of Lung Cancer”

To demonstrate and validate a breath test for detection of early stage lung cancer that could potentially reduce number of deaths.

  • Study Type: Observational
  • Study Design: Observational Model: Cohort, Time Perspective: Prospective
  • Study Primary Completion Date: December 2012

Detailed Clinical Trial Description

This is a multicenter study comparing several groups of subjects with and without lung cancer by CT scan, biopsy and the breath test. The breath test will be performed to validate the methodology and the predictive algorithm that were previously developed.

Interventions Used in this Clinical Trial

  • Device: Breath Collection Apparatus
    • Breath collected and analyzed for markers of lung cancer.

Arms, Groups and Cohorts in this Clinical Trial

  • 1
    • Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT. Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer.
  • 2
    • Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis. Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer.
  • 3
    • Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection. Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer.
  • 4
    • Apparently healthy individuals having no signs and symptoms of lung carcinoma. Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer.

Outcome Measures for this Clinical Trial

Primary Measures

  • Sensitivity and specificity of the breath test as compared to CT and pathology to support primary lung cancer diagnosis.
    • Time Frame: 30 days after completion.
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Group 1 – Asymptomatic High Risk Subjects

Inclusion Criteria

1. Patient is willing and able to cooperate with study and give signed informed consent to participate.

2. Patient has had (or will have) chest imaging with spiral CT within 7 days of breath test.

3. Age at least 18 years.

4. History of at least 10 pack-years of cigarette smoking.

5. Provide written informed consent prior to admission into the study.

Exclusion Criteria

1. Previously documented history of cancer of any site.

Group 2 – Symptomatic High Risk Subjects Without a Tissue Diagnosis

Inclusion Criteria

1. Patient is willing and able to cooperate with study and give signed informed consent to participate.

2. Patient does not have a tissue diagnosis of pulmonary disease.

3. Patient is undergoing evaluation for an unexplained pulmonary illness which is clinically consistent with lung cancer. This includes patients with unexplained symptoms (e.g. chronic unexplained cough or hemoptysis), unexplained signs (e.g. weight loss, lymphadenopathy) or unexplained investigations (e.g. an abnormal chest x-ray).

4. Actively smoking patients, as well as never smokers and former smokers are eligible for the study so long as a complete smoking consumption history can be recorded.

Exclusion Criteria

1. Previously documented history of cancer of any other site.

Group 3 – Symptomatic High Risk Subjects with a Tissue Diagnosis

Inclusion Criteria

1. Patient is willing and able to cooperate with study and give signed informed consent to participate.

2. Patient has a tissue diagnosis of a. lung cancer. or b. pulmonary disease other than lung cancer e.g. sarcoidosis, COPD, or pulmonary infection.

3. A diagnosis of lung cancer is defined as cytologic or histologic confirmation of lung cancer by bronchoscopic/thoracoscopic means, sputum cytology, percutaneous fine needle aspiration biopsy. Patients may have either non-small cell lung cancer or small cell lung cancer.

4. Breath VOC collection will be obtained prior to any invasive procedure e.g. thoracotomy, mediastinoscopy or mediastinotomy.

5. Actively smoking patients, as well as never smokers and former smokers are eligible for the study so long as a complete smoking consumption history can be recorded.

Exclusion Criteria

1. Previously documented history of cancer of any other site.

Group 4 – Apparently healthy subjects

Inclusion Criteria

1. Willingness to follow protocol requirements as evidenced by written, informed consent.

2. Healthy, male or female subjects, ages 18 and older.

3. Subjects who are non smokers having no signs or symptoms of lung carcinoma

Exclusion Criteria

1. Any active ongoing medical problems.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • Menssana Research, Inc.
  • Collaborator
    • National Heart, Lung, and Blood Institute (NHLBI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael Phillips, MD, FACP, Principal Investigator, Menssana Research, Inc.

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00639067